Publications

Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ, Stevens B.  Complement and microglia mediate early synapse loss in Alzheimer mouse models.  Science, 2016 Mar 31 [Epub ahead of print].

Head E, Lott I, Wilcock D, Lemere C.  Aging in Down Syndrome and the development of Alzheimer’s disease neuropathology.  Curr Alzheimers Res 2016;13(1):18-29. [review article].

Liu B, Le KX, Park M-A, Wang S, Belanger AP, Dubey S, Frost JL, Holton P, Reiser V, Jones PA, Trigg W, Di Carli MF, Lemere CA.  In vivo detection of age- and disease-related increases in neuroinflammation by 18F-GE180 TSPO microPET imaging in wildtype and Alzheimer’s transgenic mice.  J Neurosci 2015 Nov 25;35(47):15716-30. [Not NIH funded].

Frost JL, Liu B, Rahfeld JU, Kleinschmidt M, O'Nuallain B, Le KX, Lues I, Caldarone BJ, Schilling S, Demuth HU, Lemere CA.  An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice.  Neurobiol Aging 2015 Dec; 36(12):3187-99.  PMCID:  PMC4641825.

Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, Kenison JE, Frost JL, Le KX, Li S, Dodart JC, Caldarone BJ, Stevens B, Lemere CA.  Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline.  J Neurosci 2015 Sep 23;35(38):13029-42. [Not NIH funded].

Mably AJ, Liu W, McDonald JM, Dodart JC, Bard F, Lemere CA, O’Nuallain B, Walsh DM.  Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice.  Neurobiol Dis 2015 Jul 26;82:372-384.  PMCID:  PMC4641028.

Janota C, Lemere CA, Brito MA.  Dissecting the contribution of vascular alterations and aging to Alzheimer’s disease.  Mol Neurobiol 2015 July 5 [Epub ahead of printAbstract].

Lardenoije R, Iatrou A, Kenis G, Kompotis K, Steinbusch HWM, Mastroeni D, Coleman P, Lemere CA, Hof PR, van den Hove DLA, Rutten BPF.  The epigenetics of aging and neurodegeneration.  Prog Neurobiol 2015 Aug;131:21.64. [review article].

Janota CS, Brites D, Lemere CA, Brito MA.  Glio-vascular changes during ageing in wild-type and in Alzheimer’s disease-like APP/PS1 mice.  Brain Res 2015 Sep 16;1620:153-68.  [review article].

Mably AJ, Kanmert D, McDonald JM, Liu W, Caldarone BJ, Lemere CA, O’Nuallain B, Kosik KS, Walsh DM.  Tau immunization:  a cautionary tale?  Neurobiol Aging 2015;36(3):1316-32. [Not NIH funded].

Hartley D, Blumenthal T, Carrillo M, DiPaolo G, Esralew L, Gardiner K, Granholm A-C, Iqbal K, Krams M, Lemere C, Lott I, Mobley W, Ness S, Nixon R, Potter H, Reeves R, Sabbagh M, Silverman W, Tycko B, Whitten M, Wisniewski T.  Down syndrome and Alzheimer’s disease: common pathways, common goals.  Alzheimers Dement 2015 Jun;11(6)700-9.

An K, Klyubin I, Kim Y, Jung JH, Mably AJ, O'Dowd ST, Lynch T, Kanmert D, Lemere CA, Finan GM, Park JW, Kim TW, Walsh DM, Rowan MJ, Kim JH. Exosomes neutralize synaptic-plasticity-disrupting activity of Aβ assemblies in vivo.  Mol Brain 2013; Nov 13;6(1):47. doi: 10.1186/1756-6606-6-47 PMCID:  PMC4222117.

Wong HK, Veremeyko T, Patel N, Lemere CA, Walsh DM, Esau C, Vanderburg C, Krishevsky AM. De-repression of FOXO3a death axis by microRNA-132 and -212 causes neuronal apoptosis in Alzheimer’s disease.  Hum Mol Genet 2013 April; 22(15):3077-3092. [Not NIH funded].

Frost JL, Le KX, Cynis H, Ekpo E, Kleinschmiddt M, Palmour RM, Ervin FR, Snigdha S, Cotman CW, Saido TC, Vassar RJ, St. George-Hyslop P, Ikezu T, Schilling S, Demuth HU, Lemere CA.  Pyroglutamate-3 Aß deposition in the brains of humans,non-human primates, canines and Alzheimer’s disease-like transgenic mouse models. Am J Pathol 2013; 183(2):368-381.  PMCID: PMC3730768.

Liu B, Frost JL, Sun J, Fu H, Grimes S, Blackburn P, Lemere CA. MER5101, a Novel Aβ1-15:DT Conjugate Vaccine, Generates a Robust Anti-Aβ Antibody Response and Attenuates Aβ Pathology and Cognitive Deficits in APPswe/PS1ΔE9 Transgenic Mice. J Neurosci 2013; 33(16):7027-7037.  PMCID:  PMC3675782

Cherry JD, Liu B, Frost JL,Lemere CA, Williams JP, Olschowka JA, O’Banion MK.  Galactic Cosmic Radiation Leads to Cognitive Impairment and Increased Aβ Plaque Accumulation in a Mouse Model of Alzheimer’s Disease.  PLoS One 2012; 7(12): e53275. PMCID: PMC3534034.

Fu H, Liu B, Frost JL, Hong S, Jin M, Ostaszewski B, Shankar G, Constantino IM, Carroll MC, Mayadras TN, Lemere CA.  Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar A by microglia.  Glia 2012 May;60(6):993-1003. PMCID: PMC3325361.

Keenan B, Shulman J, Chibnik L, Towfique R, Dong T, Allen A, Corneveaux J, Lemere C, Myers A, Nicholson-Weller A, Rieman E, Evans D, Bennett D, DeJager P.  A coding variant in CR1 interacts with APOE-4 to influence cognitive decline.  Hum Mol Gen 2012 May 15;21(10):2377-88. PMCID: PMC3335317.

Frost JL, Liu B, Kleinschmidt M, Schilling S, Demuth H-U, Lemere CA.  Passive immunization against pyroglutamate-3 amyloid-ß reduces plaque burden in Alzheimer’s-like transgenic mice: a pilot study.  Neurodegener Dis 2012 10(1-4):265-70. PMCID: PMC3702016.

Lee S, Lemere CA, Frost JL, Shea TB.  Dietary supplementation with s-adenosyl methionine delayed amyloid-ß and tau pathology in 3xTg-AD mice. J Alzheimers Dis 2012;28(2):423-31.  [Not NIH funded].

Bateman RJ, Aisen PS, DeStrooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C.  Autosomal dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther 2011 Jan 6;3(1):1. PMCID:
PMC3109410

Peng Y, Xing C, Xu S, Lemere CA, Chen G, Liu B, Wang L, Feng Y, Wang X.  L-3-n-butylphthalide improves cognitive impairment induced by intracerebroventricular infusion of amyloid-beta peptide in rats. Eur J Pharmacol 2009; 621(1-3):38-45.  PMCID: 19737553.

Kadokura A, Yamazaki T, Kakuda S, Makioka K, Lemere CA, Fujjita Y, Takatama M, Okamoto K.  Phosphorylation-dependent TDP-43 antibody detects intraneuronal dot-like structures showing morphological characters of granulovacuolar degeneration.  Neurosci Lett 2009 Sep 29; 463(1):87-92.  PMID 19539703. [Not NIH funded]

Kadokura A, Yamazaki T, Lemere CA, Takatama M, Okamoto K.  Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains:  their relation to AD common pathology.  Neuropathology 2009 Oct;29(5):566-73. PMID 19422539.  [Not NIH funded]

Shankar GM, Leissring MA, Adame A, Sun X, Spooner E, Masliah E, Selkoe DJ, Lemere CA, Walsh DM.  Biochemical and immunohistochemical analysis of an Alzheimer’s disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life.  Neurobiol Dis 2009 Nov;36(2):293-302.  PMCID: PMC2782414.

Britschgi, M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DR, Holtzman DM, Jutel M, Kaye JA, Lemere CA, Leszek J, Li G, Peskind ER, Quinn JF, Yesavage JA, Ghiso JA, Wyss-Coray T.  Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer’s disease.  Proc Natl Acad Sci U S A 2009 Jul 21; 106(29): 12145-12150.  PMCID:  PMC2715538.

Baulac S, Lu H, Strahle J, Yang T, Goldberg MS, Shen J, Schlossmacher MG, Lemere CA, Lu Q, Xia W.  Increased DJ-1 expression under oxidative stress and in Alzheimer’s disease brains.  Mol Neurodegener 2009 Feb 25;4:12.  PMCID: PMC2654450.

Peng Y, Xing C, Lemere CA, Chen G, Wang L, Feng Y, Wang X.  L-3-n Butylphthalide ameliorates beta-amyloid-induced neuronal toxicity in cultured neuronal cells.  Neurosci Lett 2008;434:224-229.

Lemere CA, Oh J, Stanish HA, Peng Y, Pepivani I, Fagan AM, Yamaguchi H, Westmoreland SV, Mansfield KG. Cerebral amyloid-beta protein accumulation with aging in cotton-top tamarins: a model of early Alzheimer’s disease?   Rejuvenation Res 2008;11:321-332.

Klyubin I, Betts V, Welzel AT, Belnnow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ.  Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization.  J Neurosci 2008;28:4231-4237.

Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA.  Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/ macrophage phenotype in amyloid precursor protein transgenic mice.  J Neurosci 2008; 28:6333-6341.

Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ.  Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory.  Nat Med 2008;14:837-842.

Seabrook, TJ, Thomas K, Jiang L, Bloom J, Spooner E, Maier M, Bitan G, Lemere CA. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice.  Neurobiol Aging 2007;28:813-823.

Lemere, CA.  A beneficial role for IL-1 beta in Alzheimer disease?  J Clin Inves 2007;117:1483-1485.

He P, Zhong Z, Lindholm K, Berning L, Lee W, Lemere C, Staufenbiel M, Li R, Shen Y.  Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer’s mice.  J Cell Biol 2007;178:829-841.

Peng Y, Lee DY, Jiang L, Ma Z, Schachter SC, Lemere CA.  Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695.  Neuroscience 2007;150:386-395.

Kondo Y, Lemere CA, Seabrook TJ.  Osteopetrotic (op/op) mice have reduced microglia, no Abeta deposition, and no changes in dopaminergic neurons.  J Neuroinflammation 2007;4:31.

Seabrook TJ, Jiang L, Maier M, Lemere CA.  Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice.  Glia 2006;53:776-782.

Maier M, Seabrook TJ, Lazo ND, Jiang L, Das P, Janus C, Lemere CA.  Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer’s disease mouse model in the absence of an Abeta-specific cellular immune response.  J Neurosci 2006; 26:4717-4728.

Seabrook TJ, Jiang L, Thomas K, Lemere CA. Boosting with intranasal dendrimeric Abeta 1-15 but not Abeta 1-15 peptide leads to an effective immune response following a single injection of Abeta1-40/42 in APP-tg mice.  J Neuroinflammation 2006;5:14.

Peng, Y, Jiang L, Lee DY, Schachter SC, Ma Z, Lemere CA.  Effects of huperzine A on amyloid precursor protein processing and beta-amyloid generation in human embryonic kidney 293 APP Swedish mutant cells.  J Neurosci Res 2006;84:903-911.

Liu K, Solano I, Mann D, Lemere C, Mercken M, Trojanowski JQ, Lee VM.  Characterization of Abeta11-40/42 peptide deposition in Alzhemier’s disease and young Down’s syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer’s disease.  Acta Neuropathol 2006;112:163-174.

Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ.  Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.  Nat Med 2005;11:556-561.

Maier M, Seabrook TJ, Lemere CA.  Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monphosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT (R192G).  Vaccine 2005;23:5149- 5159.

Beglopoulos V, Sun X, Saura CA, Lemere CA, Kim RD, Shen J.  Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice.  J Biol Chem 2004;279(45):46907-46914.

Hayashi H, Kimura N, Yamaguchi H, Hasegawa K, Yokoseki T, Shibata M, Yamamoto N, Michikawa M, Yoshikawa Y, Terao K, Matsuzaki K, Lemere CA, Selkoe DJ, Naiki H, Yanagisawa K.  A seed for Alzheimer amyloid in the brain.  J Neuroscience 2004;24:4894-4902.

Seabrook TJ, Iglesias M, Bloom JK, Spooner ET, Lemere CA.  Differences in the immune response to long term Aß vaccination in C57BL/6 and B6D2F1 mice.  Vaccine 2004;22:4075-4083.

Gandy S, DeMattos RB, Lemere CA, Heppner FL, Leverone J, Aguzzi A, Ershler WB, Dai J, Frasier P, Hyslop PS, Holtzman DM, Walker LC Keller ET.  Alzheimer A beta vaccination of rhesus monkeys (Macaca mulatta).  Alzheimer Dis Assoc Discord 2004;18(1): 44-46.

Gandy S, DeMattos RB, Lemere CA, Heppner FL, Leverone J, Aguzzi A, Ershler WB, Dai J, Frasier P, Hyslop PS, Holtzman DM, Walker LC Keller ET.  Alzheimer A beta vaccination of rhesus monkeys (Macaca mulatta).  Mech Ageing Dev 2004 Feb;125(2)149-51.

Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, Zheng, JB, Seabrook TJ, Louard D, Li D, Selkoe DJ, Palmour RM, Ervin FR.  Alzheimer’s disease Aß vaccine reduces CNS Aß levels in a non-human primate, the Caribbean vervet.  Am J Pathol 2004; 165:283-297.

Seabrook TJ, Bloom JK, Iglesias M, Spooner ET, Walsh DM, Lemere CA.  Species-specific immune response to immunization with human vs. rodent Aß peptide.  Neurobiol of Aging 2004; 25:1141-1151.

Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Neve R, Ahlijanian MK, Tsai LH.  APP processing is regulated by cytoplasmic phosphorylation.  J Cell Biol 2003;163:83-95.

Lemere CA, Spooner ET, LaFrancois J, Malester B, Mori C, Leverone JF, Matsuoka Y, DeMattos RB, Holtzman DM, Clements JD , Selkoe DJ, Duff KE. Evidence for peripheral clearance of cerebral Aß protein following chronic, active Aß immunization in PSAPP mice. Neurobiol Dis 2003;14:10-18.

Lemere, CA, Spooner ET, Leverone JF, Mori C, Iglesias M, Bloom JK, Seabrook TJ.  Amyloid-beta immunization in Alzheimer's disease transgenic mouse models and wildtype mice.  Neurochem Res 2003;28:1017-1027.

Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to ß-amyloid.  J Neuroscience 2003;23:29-33.

Leverone JF, Spooner ET, Lehman H, Clements JD, Lemere CA.  Aß1-15 is less immunogenic than Aß1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting".  Vaccine 2003; 21:2197-2206.

Lemere CA, Spooner ET, Leverone JF, Mori C, Clements, JD.  Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol of Aging 2002;23:991-1000.

Spooner ET, Desai RV, Mori C, Leverone J, Lemere CA. The generation and characterization of potentially therapeutic Aß antibodies in mice: Differences according to strain and immunization protocol.  Vaccine 2002;21:290-297.

Mori C , Spooner ET, Wisniewski KE, Wisniewski TM, Yamaguchi H, Saido T, Tolan DR,  Selkoe DJ, Lemere CA.  Intraneuronal Aß42 accumulation in Down syndrome brain. Amyloid: J Protein Folding Disord 2002;9:88-102.

Lemere CA.  Comment:  Copper-zinc chelator lowers amyloid-ß protein levels in mice.  Journal Watch Neurology, Massachusetts Medical Society/ New Engl J Med 2001;3:87.

Lemere CA, Maron R, Selkoe DJ, Weiner, HL.  Nasal vaccination with ß-amyloid peptide for the treatment of Alzheimer’s disease.  DNA Cell Biol 2001;20:705-711.

Matsuoka Y, Picciano M, Malester B, LaFrancois J, Zehr C, Daeschner JM, Olshowka JA, Fonseca MI, O’Banion KM, Tenner A, Lemere CA, Duff K.  Inflamatory Response To Amyloidosis in Transgenic Mouse Model of Alzheimer’s Disease.  Am J Pathol 2001;158:1345-1354.

Kokubo H, Lemere CA, Yamaguchi H.  Localization of flotillins in human brain and their accumulation with the progression of Alzheimer’s disease pathology.  Neurosci Lett 2000;290:93-96.

Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Issazadeh S, Hancock WW, Selkoe DJ.  Nasal administration of amyloid ß-peptide decreases cerebral amyloid burden in a mouse model of Alzheimer’s disease. Ann Neurol 2000;48:567-579.

Lemere CA, Maron R, Spooner ET, Grenfell TG, Mori C, Desai R, Hancock WW, Weiner HL, Selkoe DJ.  Nasal Aß treatment induces anti-Aß antibody production and decreases cerebral amyloid burden in PDAPP mice.  Ann N Y Acad of Sci 2000;920:328-331.

Stoltzner SE, Grenfell TJ, Mori C, Wisniewski K, Wisniewski T, Selkoe DJ, Lemere CA.  Temporal accrual of complement proteins in amyloid plaques in Down syndrome with Alzheimer’s disease.  Am J Pathol 2000;156:489-499.

Lemere CA, Grenfell TJ, Selkoe DJ.  The “AMY” antigen co-occurs with Aß and follows its deposition in the amyloid plaques of Alzheimer’s disease and Down syndrome.  Am J Pathol 1999;155:29-37.

Zhen W, Han H, Anguiano M, Lemere CA, Cho C-G, Lansbury PT Jr.  Synthesis and amyloid binding properties of rhenium complexes: preliminary progress toward a reagent for SPECT imaging of Alzheimer’s disease brain.  J Med Chem 1999;42:2805-2815.

Fulton AB, Reynaud X, Hansen RM, Lemere CA, Parker C, Williams RP.  Rod photoreceptors in infant rats with a history of oxygen exposure.  Invest Opthamol Vis Sci 1999;40:168-174.

Lopera F, Ardilla A, Martinez A, Madrigal L, Arango-Viana JC, Lemere CA, Arango- Lasprilla JC, Hincapie L, Arcos-Burgos M, Ossa JE, Behrens IM, Norton J, Lendon C,  Goate AM, Ruiz-Linares A, Rosselli M, Kosik KS.  Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation.  JAMA 1997;277:793-799.

Lalowski M, Golabek A, Lemere CA, Selkoe DJ, Beavis RC, Frangione B, Wisniewski T.  “The non-amyloidogenic” p3 fragment (amyloid 17-42) is a major constituent of Down’s syndrome cerebellar preamyloid.  J Biol Chem 1996;271:33623-33631.

Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC, Yamaguchi H, Ruiz A, Martinez A, Madrigal L, Hincapie L, Arango-L JC, Anthony DC, Koo E, Goate A, Selkoe DJ, Arango JC.  The E280A presenilin 1 Alzheimer mutation produces increased A42 deposition and severe cerebellar pathology.  Nature Med 1996;2:1146-1150.

Yamaguchi H, Ishiguro K, Uchida T, Takashima A, Lemere CA, Imahori K.  Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I glycogene synthase kinase-3-beta and cyclin-dependent kinase 5, a component of TPK II.  Acta Neuropathol 1996;92:232-241.

Stephenson D T, Lemere C A, Selkoe D J, Clemens J A.  Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer’s disease brain.  Neurobiol Dis 1996;3:51-63.

Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ.  Sequence of deposition of heterogeneous amyloid -peptides and Apo E in Down syndrome:  implications for initial events in amyloid plaque formation.  Neurobiol Dis 1996; 3:16-32.

Schmidt JT, Lemere CA.  Rapid activity-dependent sprouting of optic fibers into a local area denervated by application of beta-bungarotoxin in goldfish tectum.  J Neurobiol 1996;29:75-90.

Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ.  The Swedish mutation causes early-onset Alzheimer’s disease by -secretase cleavage within the secretory pathway.  Nature Med 1995;1:1291-1296.

Munger JS, Haass C, Lemere CA, Shi G-P, Wong WS, Teplow DB, Selkoe DJ, Chapman HA.  Lysosomal processing of amyloid precursor protein to A beta peptides: a distinct role for cathepsin S.  Biochem J 1995;311:299-305.

Lemere CA, Munger JS, Shi G-P, Natkin L, Haass C, Chapman HA, Selkoe DJ.  The lysosomal cysteine protease, cathepsin S, is increased in Alzheimer’s disease and Down syndrome brain:  an immunocytochemical study.  Am J Pathol 1995;146:848-860.

Shi G-P, Webb AC, Foster KE, Knoll JH, Lemere CA, Munger JS, Chapman HA.  Human cathepsin S:  chromosomal localization, gene structure and tissue distribution.  J Biol Chem 1994; 269:11530-11536.

Yamaguchi H, Yamazaki T, Lemere C, Frosch M, Selkoe D.  Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer’s disease.  Am J Pathol 1992;141:249-259.

Hansen L, Natelson B, Lemere C, Neiman W, DeTerresa R, Regan T, Masliah E, Terry R.  Alcohol-induced brain changes in dogs.  Arch Neurol 1991;48:939-942.

Wiley C, Masliah E, Morey M, Lemere C, DeTerresa R, Grafe M, Hansen L,   Terry R.  Neocortical damage during HIV infection.  Ann Neurol 1991;29:651-657.

Murphey RK, Lemere CA.  Competition controls the growth of an identified axonal   arborization.  Science 1984;224:1352-1355.

Other Peer-Reviewed Publications

Crehan H, Lemere CA.  Anti-Amyloid-ß Immunotherapy for Alzheimer’s Disease.  In: Wolfe M Editor.  Developing Therapeutics for Alzheimer’s Disease.  Elsevier, 20152016 in press.

Messer A, Manley K, Lemere CA.  Immunotherapeutics for neurological disorders. Handbook of Therapeutic Antibodies, 2nd Edition.  Edited by Janice Reichert.   Wiley Publishers.  2014; 40:1215-30.

Lemere CA.  Immunotherapy for Alzheimer’s disease:  hoops and hurdles.  Mol Neurodegener 2013 Oct 22; 8(1):36. [Epub ahead of print].

Fu HJ, Liu B, Frost JL, Lemere CA.  Amyloid- Immunotherapy for Alzheimer’s Disease.  CNS & Neurological Disorders – Drug Targets 2010; 9:197-206.

Lemere CA, Masliah E.  Can Alzheimer’s disease be prevented by amyloid-ß immunotherapy?  Nat Rev Neurol 2010;6:108-119.

Liu B, Fu H, Frost J, Lemere CA.  Anti-Aß antibodies for the treatment of Alzheimer's  disease.  Res Prog in Alzheimer's Disease and Dementia, Sun M-K (Ed.), Nova Science  Publishers, 2009; in press.

Lemere,  CA.  Developing novel immunogens for a safe and effective Alzheimer’s disease vaccine.  Prog Brain Res; 2009. p. 83-93.

Lemere CA, Maier M, Peng Y, Jiang L, Seabrook TJ.  Novel Abeta immunogens: is shorter better?  Curr Alzheimer Res 2007;4:427-436.

Lemere CA, Maier M, Jiang L, Peng Y, Seabrook TJ.  Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer’s disease: lessons from mice, monkeys, and humans.  Rejuvenation Res 2006;9:77-84.

Maier M, Seabrook TJ, Lemere CA.  Developing novel immunogens for an effective, safe Alzheimer’s disease vaccine.  Neurodegener Dis 2005;2:267-272.

Mori C, Lemere CA.  Pathological detection of Aß and APP in brain.  In: Xia W, Xu H, 
editors.  Amyloid precursor protein: a practical approach. Boca Raton, FL: CRC Press LLC; 2004.

Kimberly WT, Kovacs DM, Walsh D, Lashuel H, Lemere CA.  Meeting Report:  The 8th International Conference on Alzheimer's disease and Related Disorders (July 20-25, 2002; Stockholm, Sweden). Amyloid:  J Protein Folding Disord 2003; 10:51-61.

Lemere CA, Spooner ET, Leverone JF, Clements JD.  Improvements in intranasal amyloid-ß(Aß) immunization in mice.  In: Selkoe DJ, Christen Y, editors.  Immunization against Alzheimer’s disease and other neurodegenerative disorders.  Berlin: Springer-Verlag; 2003. p. 59-74.

Lemere CA, Seabrook TJ, Iglesias M, Mori C, Leverone JF, Spooner ET.  Modulating amyloid-beta levels by immunotherapy: A potential therapeutic strategy for the prevention and treatment of Alzheimer’s disease. In: Saido TC, editor.  Amyloid-beta metabolism and Alzheimer’s disease. Georgetown, TX: Landes Bioscience, Eureka.com; 2002. p. 145-161.

Kosik KS, Ho C, Liyange U, Lemere CA, Medina M, Shou J.  A novel gene in the Armadillo family interacts with Presenilin 1.  In: Wang E, Snyder DS, editors.  Handbook of the aging brain. San Diego: Academic Press; 1998. p. 171-180.

Selkoe DJ, Xia W, Zhang J, Podlisny MB, Lemere CA, Citron M, Koo EH.  Mechanistic studies of the effect of presenilins 1 and 2 on APP metabolism.  In: Younkin S, Tanzi R, Christen Y, editors. Presenilins and Alzheimer’s disease.  Berlin: Springer-Verlag; 1997. p. 49-58.